An initial experience program was conducted in patients with COPD to collect patient reported feedback about newly initiated therapy with fluticasone propionate/salmeterol 250/50 (FSC).
Patients completed 2 surveys; one at baseline (before initiating therapy with FSC 250/50) and one targeted for 30 days after starting therapy with FSC 250/50). The first survey collected patient demographics, duration of COPD diagnosis, smoking history, and satisfaction with prior treatment. The second survey assessed patient perceived impact of FSC 250/50 on breathing, and convenience and satisfaction with FSC therapy.
A total of 973 patients completed both surveys. Completers were mostly female (62%), and 87% were ≥ 45 years of age. Two-thirds of the completers had been diagnosed with COPD for ≥ 1 year. At baseline, 58% of the population used prescription medications prior to starting FSC 250/50. The most common medications were ipratropium/albuterol (37%) and salmeterol (27%). Patients reported satisfaction with their prior therapy (5.52 on a 9 point scale), but 22% of patients were quite dissatisfied (1-3 on a 9 point scale). The second survey, completed an average of 51 days after starting FSC 250/50, showed that patients perceived improvement in their breathing overall (6.82 on a 9 point scale) and had a high level of satisfaction with FSC 250/50 (7.76 on a 9 point scale). Less than 4% of patients were quite dissatisfied (<3 on a 9 point scale). FSC 250/50 was regarded as a very convenient medication (8.12 on a 9 point scale).
Patients with COPD reported a high level of satisfaction with their treatment an average of 51 days after initiating therapy with FSC 250/50.
High patient satisfaction with therapy may encourage increased compliance with therapy and therefore may result in improved outcomes.
Stuart Stoloff, Grant monies (from industry related sources) Received research grants from GlaxoSmithKline; Consultant fee, speaker bureau, advisory committee, etc. Received consultant fees from GlaxoSmithKline and serve on speaker bureau and advisory board for GlaxoSmithKline